In vitro antifungal activity of isavuconazole against Madurella mycetomatis

Wendy Kloezen*, Jacques F. Meis, Ilse Curfs-Breuker, Ahmed H. Fahal, Wendy W.J. Van De Sande

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

42 Citations (Scopus)

Abstract

Currently, therapy of black-grain mycetoma caused by Madurella mycetomatis consists of extensive debridement of the infected tissue combined with prolonged antifungal therapy with ketoconazole or itraconazole. In the present study, the in vitro activity of the new triazole isavuconazole toward M. mycetomatis was evaluated. Isavuconazole appeared to have high activity against M. mycetomatis, with MICs ranging from≤0.016 to 0.125 μg/ml. Due to its favorable pharmacokinetics, isavuconazole could be a promising antifungal agent in the treatment of mycetoma.

Original languageEnglish
Pages (from-to)6054-6056
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number11
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Dive into the research topics of 'In vitro antifungal activity of isavuconazole against Madurella mycetomatis'. Together they form a unique fingerprint.

Cite this